Lipid Nanoparticles Global Market Report 2024 by The Business Research Company | Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Bayer AG; Abbott Laboratories; Amgen Inc; The Merck Group; Evonik Industries AG; BioNTech SE; Moderna Inc.

The lipid nanoparticles (LNPs) market size has grown rapidly in recent years. It will grow from $0.89 billion in 2023 to $1.04 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to rising focus on the development of lnp-based drugs, strong investment in research infrastructure, increasing healthcare expenditures.

The lipid nanoparticles (LNPs) market size is expected to see rapid growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to rising prevalence of chronic diseases, increasing demand for rna-based therapeutics, increasing demand for advanced gene delivery systems, this increasing focus on personalized medicine, increasing investment in research and development. Major trends in the forecast period include advancements in drug delivery technologies, innovative drug delivery systems, integration of artificial intelligence in lnp development.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=15082&type=smp

Lipid Nanoparticles Market Major Segments
The lipid nanoparticles market covered in this report is segmented -

1) By Type: Nano-Structured Lipid Carriers (NLCs), Solid Lipid Nanoparticles (SLNs), Other Types
2) By Application: Research, Therapeutics
3) By End User: Pharmaceutical And Biotechnology Companies, Academics And Research Centers, Other End Users

Key Driver - Lipid Nanoparticles Revolutionizing Chronic Disease Management Amid Rising Prevalence

The rising prevalence of chronic diseases is propelling the growth of the lipid nanoparticles (LNPs) market. A chronic disease is a condition that remains over a long period, usually over three months, and includes diabetes, hypertension, and other diseases. Chronic disease rates are increasing due to factors like poor health behaviors, aging populations, lifestyle choices, tobacco use, poor nutrition, physical inactivity, and excessive alcohol consumption. Lipid nanoparticles (LNPs) are a practical approach to chronic disease management due to their ability to enhance the effectiveness of mRNA therapeutics and vaccines. Lipid nanoparticles (LNPs) improve the treatment landscape for various chronic diseases, offering hope for more effective management options and potentially better patient outcomes. For instance, in 2021, according to the data published by the International Diabetes Federation, a Belgium-based diabetes awareness foundation, in 2021, 537 million adults between the ages of 20 and 79 were living with diabetes, and this number is projected to reach 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of chronic diseases is driving the growth of the lipid nanoparticle market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=15082&type=smp

Prominent Trend - Innovation In Lipid Nanoparticle Formulations Propel Companies To Forefront The Biotech Market

Major companies operating in the lipid nanoparticles (LNPs) market are innovating circular RNA (circRNA) and lipid nanoparticle (LNP) formulations to gain a competitive edge. The expansion of circular RNA (circRNA) and lipid nanoparticles (LNP) formulation offers a more comprehensive range of RNA formats, including circRNA, a single-stranded RNA forming a covalently closed loop. For instance, in September 2023, GenScript Biotech, a US-based life sciences company, expanded its reagent services to include circular RNA (circRNA) and lipid nanoparticles (LNP) formulation. These new services are part of GenScript's commitment to provide protein replacement therapies and gene and cell therapy, and they are available immediately as part of GenScript's contract-manufactured reagent services. CircRNA has several advantages over traditional linear RNA, such as higher stability, slower degradation, and achieving desirable therapeutic protein levels with a lower dosage.

Lipid Nanoparticles Market Players
Major companies operating in the lipid nanoparticles market report are Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Bayer AG; Abbott Laboratories; Amgen Inc; The Merck Group; Evonik Industries AG; BioNTech SE; Moderna Inc.; Sanofi SA; Solid Biosciences Inc.; AstraZeneca PLC; NOF Corporation; Alnylam Pharmaceuticals Inc.; Nanomerics Ltd.; CordenPharma International; Nippon Fine Chemical; Helix Biotech Inc.; Dicerna Pharmaceuticals; Gattefossé SAS; Arbutus Biopharma; Avanti Polar Lipids; IOI Oleo GmbH; Evox Therapeutics Ltd.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/lipid-nanoparticles-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the lipid nanoparticles market in 2023. The regions covered in the lipid nanoparticles market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Lipid Nanoparticles Market Report Structure
3. Lipid Nanoparticles Market Trends And Strategies
4. Lipid Nanoparticles Market - Macro Economic Scenario
5. Lipid Nanoparticles Market Size And Growth
…..
27. Lipid Nanoparticles Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.